

Landmarks in animal virus research: The early period (From Virology- Fields 2002)



DATA	Virologist	DISCOVERY
1898	Loeffler F. Frosch P.	First filterable animal virus
1898	Sanarelli G.	Myxomatous virus
1901	Reed W.	First human virus (YFV)
1903	Remingler P. , Riffat-Bay	Rabies virus
1903	Negri A.	The body inclusion of rabies virus
1908	Ellerman V., Bang O.	First leukemia-causing virus
1909	Landsteiner K., Popper E.	Poliovirus
1911	Rous P.	First solid tumor-causing virus

Landmarks in animal virus research: The early period (From Virology- Fields 2002)

DATA	Virologist	DISCOVERY
1898	Loeffler F. Frosch P.	First filterable animal virus
1898	Sanarelli G.	Myxomatous virus
1901	Reed W.	First human virus (YFV)
1903	Remingler P. , Riffat-Bay	Rabies virus
1903	Negri A.	The body inclusion of rabies virus
1908	Ellerman V., Bang O.	First leukemia-causing virus
1909	Landsteiner K., Popper E.	Poliovirus
1911	Rous P.	First solid tumor-causing virus



Timeline | Some major discoveries and events during the first century of tumour virology



Peyton Rous

Born: 5 October 1879, Baltimore, MD, USA

Died: 16 February 1972, New York, NY, USA

Affiliation at the time of the award:

Rockefeller University, New York, NY, USA

Prize motivation: "for his discovery of tumour-inducing viruses"

Nobel Lecture

Nobel Lecture, December 13, 1966

The Challenge to Man of the Neoplastic Cell



Renato Dulbecco

Born: 22 February 1914, Catanzaro, Italy

Died: 19 February 2012, La Jolla, CA, USA


Affiliation at the time of the award: Imperial Cancer Research Fund Laboratory, London, United Kingdom

Prize motivation: "for their discoveries concerning the interaction between tumour viruses and the genetic material of the cell"

1975, The Nobel Prize in Physiology or Medicine



Etiology of cancer in man



Etiology of cancer in man: role of infectious diseases

Total	15-16%	
	9%	Westerns countries
	21%	Developing countries

Infectious agents may induce the development of cancer


Mechanism	Trasforming action	Example
Genetic	Modifications on cellular DNA expression	carcinoma uterine cervix (HPV)
Inflammatory	Chronic inflammatory response	epatocarcinoma (HBV)
Immunodepressive	No response to cancer development	Kaposi sarcoma (HHV-8)

Mechanism of transformation

In vivo and epidemiological studies indicate that transformation is a **multi-step process** involving: **initiation**, **promotion** and **progression**



Normal Cell

Neoplastic Cell



The oncogenic virus may be necessary but not sufficient to produce neoplasia

Multifactorial induction of cancer: Molecular determinants



**Virus-induced
perturbation**

Common characteristics of viral oncogenic transformation

- A single infectious virus particle is sufficient for transformation
- Virus induced transformation is a “single hit” process
- All or part of the viral genome persist in the transformed cell. In virtually all cases of virus-induced transformation at least part of the viral genome is expressed in the transformed cells
- Transformation results from corruption of normal cell growth and cell-division signals
- Reversion of the transformed cellular phenotype can be achieved by specific interference with the function of viral effector

Oncogenic viruses

***RNA
Viruses***

Acquire genes involved
in signal trasduction
and then in cell proliferation;
Cellular oncogenes

Transformation

Tumors

***DNA
Viruses***

Adopte a strategy to inactivate
key tumor-suppressor proteins;
NO cellular oncogenes

Transformation

Tumors

Oncogenic viruses

RNA viruses

- The replication is not cytotoxic. Transformation is compatible with the production of infectious progeny
- Virus production is not a prerequisite of oncogenesis
- Virus oncogenes are not essential for viral replication
- Only one virus family does exist

DNA viruses

- The synthesis of infectious progeny is linked to cell death
- Transformation can occur only if the viral cycle is aborted
- The oncogenic potential is linked to the genetic strategy of virus replication
- Seven different groups do exist

Tabella 38.1 Virus associati a tumori dell'uomo.


DEOSSIRIBOVIRUS		
Famiglia	Virus	Tumori associati
<i>Herpesviridae</i>	Virus Epstein-Barr HSV-2 HHV-8	Linfoma di Burkitt Linfomi a cellule B, carcinoma nasofaringeo Carcinoma della cervice uterina Sarcoma di Kaposi, linfomi cavitari
<i>Papillomaviridae</i>	Papilloma	Papillomi e carcinomi cutanei, genitali e laringei
<i>Polyomaviridae</i>	JC e BK MCPyV	Tumori in modelli animali Carcinoma a cellule di Merkel
<i>Hepadnaviridae</i>	HBV	Carcinoma epatocellulare primario
<i>Poxviridae</i>	Mollusco contagioso	Iperplasia nodulare epidermica
RIBOVIRUS		
Famiglia	Virus	Tumori associati
<i>Retroviridae</i>	HTLV-1 HIV-1, HIV-2	Linfomi e leucemia a cellule T dell'adulto Sarcoma di Kaposi, linfoma non-Hodgkin, cancro cervicale; tumori non-AIDS correlati
<i>Flaviviridae</i>	HCV	Carcinoma epatocellulare primario

**Oncogenic RNA viruses:
RETROVIRUS**


Oncogenic RNA viruses

Taxonomic grouping	Examples	Tumor Types
Retroviridae		
Mammalian B type	Mouse mammary tumor virus	Mammary carcinoma, T-cell lymphoma, Leukemia
Mammalian C type	Murine leukemia viruses Gross leukemia virus Moloney leukemia virus Graffi leukemia virus Friend leukemia virus Moloney sarcoma virus Kirsten sarcoma virus Harvey sarcoma virus Feline leukemia viruses Gardner-Amstein feline sarcoma virus McDonough feline sarcoma virus Simian sarcoma virus	Leukemia, lymphoma, sarcoma, various other malignancies and pathologic conditions
Avian C type	Avian leukosis and sarcoma viruses Rous sarcoma virus Rous-associated viruses (RAV) Avian leukosis viruses Avian myeloblastosis virus Avian erythroblastosis virus Mill-Hill 2 virus Myelocytoma virus MC29	Sarcoma, B-cell lymphoma, myeloid and erythroid leukemia, various carcinomas and other tumors
HTLV-BLV	Human T-lymphotropic virus Bovine leukemia virus	T-cell leukemia B-cell lymphoma

RETROVIRUS replication




RETROVIRUS genome




Enhancer

Promoter

RETROVIRUS genomes : DIFFERENT MECHANISMS OF ONCOGENESIS




RETROVIRUS genomes : DIFFERENT MECHANISMS OF ONCOGENESIS




Non acute transformation by RNA tumor viruses: insertional mutagenesis

cellular genome




CATEGORY OF ONCOGENE (EXAMPLE)	FUNCTION OF c-onc	ALTERATION IN v-onc RELATIVE TO c-onc	ACTION OF v-onc
PTK protein tyrosine kinase (<i>src</i>)	Tyrosine phosphorylation activates intracellular signaling proteins	Loss of C terminal tyrosine or loss of receptor binding domain	Increase tyrosine phosphorylation causes sustained intracellular signaling
Serine-threonine kinase(<i>mos</i>)	Phosphorylation activates cell cycle proteins	Deletion of N terminal regulatory sequences	Increase phosphorylation activates cell cycle
G-protein (<i>ras</i>)	Cycles between GTP/GDP forms regulating signaling	Change in amino acid at codon 12	High GTP/GDP ratio causes sustained activation signals
Transcription factor (<i>myb</i>)	Interactions with transcription complex to enhance or reduce transcription	Deletion of regulatory domains or increase of mRNA or protein accumulation	Increase transcription of growth factors or cell cycle genes or reduction of anti-oncogene expression

RETROVIRUS genomes : DIFFERENT MECHANISMS OF ONCOGENESIS



Acute transformation by RNA tumor viruses: expression of viral/cellular oncogene


cellular genome




Oncogeni di Retrovirus a trasformazione acuta

src	Rous sarcoma virus	Chicken
myc	Avian myelocytomatosis virus	Chicken
erb A, erb B	Avian erythroblastosis virus	Chicken
myb	Avian myeloblastosis virus	Chicken
ets	Avian erythroblastosis virus	Chicken
rel	Avian reticuloendotheliosis virus	Turkey
H-ras	Harvey rat sarcoma virus	Rat
K-ras	Kirsten murine sarcoma virus	Mouse
abl	Abelson murine leukemia virus	Mouse
raf	Murine sarcoma virus	Mouse
fos	Mouse osteosarcoma virus	Mouse
fms	Feline sarcoma virus	Cat
fes	Feline sarcoma virus	Cat
sis	Simian sarcoma virus	Monkey


RETROVIRUS genomes : DIFFERENT MECHANISMS OF ONCOGENESIS



Transactivation by regulatory viral genes



PUTATIVE TRANSFORMING ACTION OF HTLV-I






Figura 38.4 Schema del meccanismo trasformante di HTLV-1. Il prodotto del gene *tax* di HTLV-1 è in grado di transattivare non solo geni virali ma anche geni cellulari fra cui quelli codificanti l'IL-2 e il suo recettore. L'attivazione di IL-2 è responsabile della proliferazione e immortalizzazione dei linfociti T.

CARACHETISTICS OF ONCOGENIC RETROVIRUSES

CATEGORY	Incubation period	MECHANISM	REPLICATION	EXAMPLE
Acute transforming	Weeks Uncommon	Viral oncogenes	Defective	ASV MSV FeSV
Non-acute transforming	Years Common	Insertional mutagenesis and up-regulation of cellular oncogenes	Replication Competent	MuLV ALV FeLV
Trans-acting transforming	Years Uncommon	Transactivation of viral regulatory genes	Replication competent	HTLV 1 BLV

Oncogenic RETROVIRUS:
in human pathology only
Human T cell Leukemia Virus
type I (HTLV-I)

HTLV-1

- The first human retrovirus to be discovered, isolated from a patient with cutaneous T cell lymphoma in 1980
- Infects 10-20 million people worldwide from seroprevalence studies
- Disease only manifests in approx 5% of infected patients
- Primarily transmitted by breast feeding, although spread via blood transfusion, sharing of needles, and sexual intercourse also occurs
- Endemic in southern Japan, the Caribbean, South America, the Melanesian islands, Papua New Guinea, the Middle East and central/southern Africa
- Seroprevalence increases with age, women are twice as likely to be infected as men in endemic areas (only seen after 30 yrs of age and probably 2/2 sexual transmission)
- In non-endemic areas like US and Europe the seroprevalence is less than 1%
- Human T-lymphotropic virus type-1 (HTLV-1) is the causative agent of adult T-cell leukaemia/lymphoma (ATL), an aggressive CD4+ T-cell malignancy (and neurological disorders including myelopathy/Tropical spastic paraparesis).

Tabella 38.1 Virus associati a tumori dell'uomo.

DEOSSIRIBOVIRUS		
Famiglia	Virus	Tumori associati
<i>Herpesviridae</i>	Virus Epstein-Barr HSV-2 HHV-8	Linfoma di Burkitt Linfomi a cellule B, carcinoma nasofaringeo Carcinoma della cervice uterina Sarcoma di Kaposi, linfomi cavitari
<i>Papillomaviridae</i>	Papilloma	Papillomi e carcinomi cutanei, genitali e laringei
<i>Polyomaviridae</i>	JC e BK MCPyV	Tumori in modelli animali Carcinoma a cellule di Merkel
<i>Hepadnaviridae</i>	HBV	Carcinoma epatocellulare primario
<i>Poxviridae</i>	Mollusco contagioso	Iperplasia nodulare epidermica
RIBOVIRUS		
Famiglia	Virus	Tumori associati
<i>Retroviridae</i>	HTLV-1 HIV-1, HIV-2	Linfomi e leucemia a cellule T dell'adulto Sarcoma di Kaposi, linfoma non-Hodgkin, cancro cervicale; tumori non-AIDS correlati
<i>Flaviviridae</i>	HCV	Carcinoma epatocellulare primario

Other oncogenic RNA viruses

- HIV
 - DIRECT - Tat protein
 - INDIRECT - Immunosuppression
- HCV
 - INDIRECT - Liver regeneration


DNA VIRUSES (1)

- Most DNA viruses of eukaryotes transcribe and replicate their genomes and assemble progeny **in the nucleus**, the site of cellular DNA transcription and replication. The exceptions are the poxviruses, iridoviruses, and African swine fever virus, which replicate their DNA genomes partly or completely in the cytoplasm.
- DNA virus use **host cell enzymes for transcription**
- **Early in infection, a subset of so-called immediate early viral genes is expressed to produce mostly catalytic amounts of the nonstructural proteins required for DNA replication and modulation of the intracellular environment**
- **Sometimes these early events can lead to neoplastic transformation**
- Most viruses with small DNA genomes use host cell enzymes for **DNA replication**; those with intermediate and large size genomes have sufficient genetic capacity to encode DNA polymerases
- After genome replication, a different subset of genes is expressed (**late genes**) that directs synthesis of stoichiometric amounts of the **structural proteins** required for progeny virus assembly


DNA VIRUSES (2)

- **Because cellular DNA synthesis occurs only during the S-phase of the cell cycle and not at all in terminally differentiated G0 cells, viruses that depend on the DNA polymerases of the host must either wait for infected cells to enter S-phase spontaneously, as do parvoviruses, or early in infection they must express one or more viral oncogenes to override the regulation imposed by the cell cycle control proteins p53 and pRb and thereby stimulate infected cells to enter S-phase prematurely, as do polyoma- and papillomaviruses, among others.**
- **Viruses with large DNA genomes (e.g., herpes- and poxviruses) encode some of these enzymes themselves, and can thus replicate in nondividing cells** and other environments that would otherwise be inhospitable for DNA replication, such as terminally differentiated cells of the nervous system (some herpesviruses) or even the cytoplasm (poxviruses).


Tumor DNA viruses




ACTION OF THE RETINOBLASTOMA PROTEIN (Rb)



ACTION OF THE RETINOBLASTOMA PROTEIN (Rb)




ACTION OF THE RETINOBLASTOMA PROTEIN (Rb)



DNA tumor viruses: Viral proteins that inactivate cellular oncogenes (pRb)


Virus	Viral protein that complexes with pRb cellular anti-oncoprotein
Simian virus 40	Large T antigen
Human papillomavirus	E7
Adenovirus	E1A
Human herpes virus 8	LANA
Epstein-Barr virus	EBNA 3C

ACTION OF THE p53 PROTEIN




DNA replication and mitosis are dependent on the activity of **cyclin**-dependent protein kinase (**CDK**) enzymes, which are heterodimers of a catalytic subunit with a **cyclin** subunit

ACTION OF THE p53 PROTEIN



DNA replication and mitosis are dependent on the activity of **cyclin**-dependent protein kinase (**CDK**) enzymes, which are heterodimers of a catalytic subunit with a **cyclin** subunit

ACTION OF THE p53 PROTEIN



DNA replication and mitosis are dependent on the activity of **cyclin**-dependent protein kinase (**CDK**) enzymes, which are heterodimers of a catalytic subunit with a **cyclin** subunit

DNA tumor viruses: Viral proteins that inactivate cellular oncogenes (p53)

Virus	Viral protein that complexes with p53 cellular anti-oncoprotein	
Simian virus 40	Large T antigen	
Human papillomavirus	E6	
Adenovirus	E1B	
Human herpes virus 8	LANA	




Figura 38.1 A. Interazione di oncoproteine prodotte da alcuni deossiribovirus con la proteina p105RB. Le proteine precoci E1A di adenovirus (Ad E1A) e T-grande del poliomavirus SV40 (SV40 TAg) possono interagire con la forma attiva ipofosforilata della proteina p105RB formando un complesso che porta alla liberazione del fattore di trascrizione E2F-1, il quale può così attivare la trascrizione di geni specifici che permettono alla cellula di entrare nella fase S. **B. Interazione di oncoproteine prodotte con la proteina p53.** Le proteine E1B di adenovirus (Ad E1B) e T-grande del poliomavirus SV40 (SV40 TAg) si legano alla proteina p53 inattivando la sua funzione.




Figura 38.2 A. Interazione della oncoproteina E6 di papilloma virus con prodotti cellulari. La proteina precoce E6 può portare alla degradazione di p53 dopo formazione del complesso trimerico con E6AP e p53. E6 è anche in grado di interagire con hTERT e di bloccare l'apoptosi mediante interazione con BAX e BAK. **B.** Interazione della oncoproteina E7 di papillomavirus con prodotti cellulari. La proteina precoce E7 può interagire con la forma attiva ipofosforilata della proteina p105RB portando alla liberazione del fattore di trascrizione E2F-1, il quale può così attivare la trascrizione di geni coinvolti nella proliferazione cellulare. Inoltre E7 deregola il ciclo cellulare inibendo gli inibitori delle chinasi ciclico-dipendenti come p21 e p27 o interagendo direttamente con CDK2. E7 induce anche instabilità genomica interagendo con la tubulina- γ e attivando la trascrizione di geni cellulari mediante interazione con gli istoni deacetilasi (HDAC).

Other oncogenic DNA viruses

- HHV-8
 - DIRECT
 - Sequence homology with cellular genes involved in apoptosis, cell proliferation and immune response
- HSV-1
 - DIRECT
 - Insertional mutations, cis-activation of protooncogenes
- HSV-2
 - DIRECT
 - Insertional mutations, cis-activation of protooncogenes
- HBV
 - DIRECT
 - Insertional mutations, cis-activation of protooncogenes
 - INDIRECT
 - Liver regeneration

In most (approximately 90%) of the cases of Burkitt's lymphoma, a reciprocal translocation has moved the proto-oncogene *c-myc* from its normal position on chromosome 8 to a location close to the immunoglobulin (Ig) heavy-chain gene enhancer on chromosome 14. ENHANCEMENT OF GROWTH ACTIVATORS





Figura 38.3 Traslocazione cromosomica nel linfoma di Burkitt. Nella traslocazione più frequente osservata in questo linfoma (8;14) l'oncogene *c-myc* presente sul cromosoma 8 viene portato sul cromosoma 14 in prossimità dei geni che codificano per la porzione costante delle catene pesanti delle immunoglobuline.



Murray et al
 Medical Microbiology
 Seventh Edition 2013